<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04323852</url>
  </required_header>
  <id_info>
    <org_study_id>13312</org_study_id>
    <secondary_id>ISRCTN44896820</secondary_id>
    <secondary_id>IRCT20180118038423N1</secondary_id>
    <nct_id>NCT04323852</nct_id>
  </id_info>
  <brief_title>Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery?</brief_title>
  <official_title>Vitamin D Treatment Attenuates Heart Apoptosis After Coronary Artery Bypass Surgery; A Double-Blind Randomized Placebo-Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and study aim:&#xD;
&#xD;
      Heart diseases are among the most common causes of death worldwide. A large proportion of&#xD;
      deaths are caused by heart attacks (myocardial infarction), where blood flow to the heart is&#xD;
      reduced resulting in damage to the heart muscle. If the arteries supplying blood to the heart&#xD;
      start to become blocked, Coronary Artery Bypass Grafting (CABG) surgery is a treatment to&#xD;
      replace the blocked sections of artery can reduce angina (chest pain). However, CABG surgery&#xD;
      has complications, including an increased risk of heart attack. Vitamin D deficiency is&#xD;
      thought to be linked to poorer recovery from heart attack and CABG surgery. This study aims&#xD;
      to investigate if vitamin D supplementation can reduce injury to the heart following CABG&#xD;
      surgery.&#xD;
&#xD;
      Who can participate? Adults with vitamin D deficiency undergoing CABG&#xD;
&#xD;
      What does the study involve? Participants are randomly allocated to one of two groups. Those&#xD;
      in the first group receive vitamin D at 3 doses per day for 3 days before surgery. The second&#xD;
      group will receive a dummy pill (placebo). Both groups will have standard CABG surgery.&#xD;
&#xD;
      What are the possible benefits and risks of participating? Those in the vitamin D group might&#xD;
      benefit from its effects. Vitamin D has few side effects, especially when taken for only a&#xD;
      few days.&#xD;
&#xD;
      Where is the study run from? Shahid Modarres Hospital (Iran)&#xD;
&#xD;
      When is the study starting and how long is it expected to run for? September 2017 to January&#xD;
      2019&#xD;
&#xD;
      Who is funding the study? Deputy of Research of Shahid Beheshti School of Medicine&#xD;
&#xD;
      Who is the main contact? Dr Erfan Tasdighi erfan.tasdighi@gmail.com&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrollment started in June 2018 and was completed in December 2018. The inclusion criteria&#xD;
      were as following: the patients referred for elective and isolated Coronary Artery Bypass&#xD;
      Graft (CABG) using Cardiopulmonary Bypass (CPB) with vitamin D deficiency (defined as&#xD;
      25-hydroxyvitamin D [25(OH) D] &lt; 20 ng/mL) and normal kidney function (creatinine &lt;1.5mg/dL).&#xD;
      The exclusion criteria were: recent myocardial infarction, urgent CABG, non-isolated coronary&#xD;
      surgery, redo surgery, malignant disease, presence of acute or chronic inflammatory diseases,&#xD;
      history of vitamin D treatment within previous 6 months, or unwillingness to participate.&#xD;
&#xD;
      Intervention Following informed consent, eligible study participants were randomly assigned&#xD;
      (by using a computer- generated random code) in a 1:1 ratio to receive either placebo or a&#xD;
      total of 450,000 international units (IU) vitamin D3 (three 50,000 IU of vitamin D3 tablet&#xD;
      daily for 3 days) before operation. The placebo group received three inactive medication&#xD;
      tablets daily at the same time point. With the exception of the pharmacists, all the&#xD;
      investigators, patients and the medical team were blinded to the group allocation.&#xD;
&#xD;
      Coronary artery bypass was done in the culprit lesions for both groups by one surgical team.&#xD;
      The standard protocol for general anesthesia, surgical and CPB management were performed for&#xD;
      all patients and have already been described in detail [16].&#xD;
&#xD;
      Outcome measures The primary outcome was the degree of heart apoptosis by measurement of&#xD;
      caspase 2, 3 and 7 activity from right atrial specimen with immunohistochemistry staining,&#xD;
      and the serum level of anti-inflammatory interleukin-10 (IL-10) and insulin- like growth&#xD;
      factor (IGF-1), and N-terminal pro v-type Brain Natriuretic Peptide (nt-pro BNP). The biopsy&#xD;
      from right atrial appendage was taken at the end of surgery after venous cannula removal in a&#xD;
      nontraumatic fashion, kept into formalin and in less than 24h parafinized. Blood samples were&#xD;
      collected at the baseline (T1), before anesthesia induction (T2), at the end of surgery after&#xD;
      protamine reversal (T3) and the first postoperative day (T4) to measure the serum level of&#xD;
      IGF-1, IL-10 and pro BNP. The blood samples were centrifuged at 2500 rpm for 15 min within&#xD;
      one hour after blood sampling, and the serum was stored at -20°C until assayed.&#xD;
&#xD;
      Enzyme-linked immunosorbent assay The concentration of IL-10 was measured by a quantitative&#xD;
      ELISA kit . The concentration of the IGF- 1 was measured by a quantitative ELISA kit .&#xD;
&#xD;
      Serum vitamin D was detected by using the high performance liquid chromatography method . The&#xD;
      pro BNP measurement was done using a commercially available two- site chemiluminescent&#xD;
      immunometric assay .&#xD;
&#xD;
      Immunohistochemistry studies Immunohistochemical staining was performed on 5-micrometer thick&#xD;
      sections. The slides were incubated at 37°C for 24 hours and de-paraffinized in pre-heated&#xD;
      xylene and rehydrated through descending grades of alcohol, washed in distilled water. Heat&#xD;
      induced antigen retrieval was done by microwave oven with citrate buffer (pH 6.0) for&#xD;
      anti-caspase-7 and Ethylenediamine Tetraacetic Acid; buffered solution (Tris-EDTA) (pH=8) for&#xD;
      anti-caspase-2 and 3. endoperoxidase blocking was done by adding hydrogen peroxide on the&#xD;
      sections. The protein block then added for 5 minutes, slides were washed in Tris-Buffered&#xD;
      Saline (TBS). .The primary antibody as anti-caspase-2 antibody, rabbit monoclonal ,&#xD;
      anti-caspase-3 antibody, rabbit monoclonal , anti-caspase-7 antibody, and mouse monoclonal&#xD;
      (clone 7-1-11 , abcam) antibody were added and kept for 30 minutes, washed in TBS. Mouse and&#xD;
      Rabbit Specific horseradish peroxidase/Diaminobenzidine (HRP/DAB) immunohistochemistry (IHC)&#xD;
      Detection Micro-polymer Kit were used and incubated for 15 minutes then washed with&#xD;
      tris-buffered saline (TBS). Diaminobenzidine (DAB) chromogen was added and kept for 5&#xD;
      minutes. Slides washed in distilled water and counter stained with hematoxylin. Sections&#xD;
      containing lymph node tissue were used as positive control. Negative control included primary&#xD;
      antibody replaced with phosphate buffered saline (PBS). Immunostained sections were reviewed&#xD;
      for cytoplasmic expression of anti-caspase-2, anti-caspase-3 and anti-caspase-7. The number&#xD;
      of immune-reactive cells per High Power Field (HPF) (X 400) was counted. For this purpose at&#xD;
      least 10 HPF were assessed and the average of positive cells was recorded.&#xD;
&#xD;
      Sample size and statistical methods The determination of the patient number (30 patients per&#xD;
      group) was based on previous trials investigating the caspase activity in the CABG setting .&#xD;
&#xD;
      Categorical variables were reported as numbers and percentages, whereas mean± standard&#xD;
      deviation was expressed for continuous variables. Repeated measures of analysis of variance&#xD;
      and multiple comparisons using the Bonferroni correction (type I error correction) were&#xD;
      applied for evaluating the change of measured inflammatory markers between the groups over&#xD;
      time. The Kolmogorov-Smirnov test for normality was performed. Continuous variables and&#xD;
      categorical variables were compared between groups using Student's t test (or Mann-Whitney&#xD;
      test for those meeting abnormal distribution) and Chi-square, respectively. All the&#xD;
      statistical analyses were performed using SPSS version 23 (SPSS, Chicago, IL, USA). A p&#xD;
      values &lt;0.05 was considered to be significant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">January 21, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>With the exception of the pharmacists, all the investigators, patients and the medical team were blinded to the group allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Caspase 2 Enzyme Level</measure>
    <time_frame>during the surgery, an average of 3 hours</time_frame>
    <description>Caspase 2 enzyme activity in right atrial specimen measured by with immunohistochemistry staining The positive control and negative control were taken from human lymph node tissue. as for the control tissue a humane lymph node was used. Positivity for active caspase is shown using cytoplasmic staining . the number of apoptotic cells was measure per each high power filed (HPF) under light microscopy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Caspase 3 Enzyme Level, an Average of 3 Hours</measure>
    <time_frame>during the surgery, an average of 3 hours</time_frame>
    <description>Caspase 3 enzyme activity in right atrial specimen measured by with immunohistochemistry staining The positive control and negative control were taken from human lymph node tissue. as for the control tissue a humane lymph node was used. Positivity for active caspase is shown using cytoplasmic staining . the number of apoptotic cells was measure per each high power filed (HPF) under light microscopy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Caspase 7 Enzyme Level</measure>
    <time_frame>during the surgery, an average of 3 hours</time_frame>
    <description>Caspase 7 enzyme activity in right atrial specimen measured by with immunohistochemistry staining The positive control and negative control were taken from human lymph node tissue. as for the control tissue a humane lymph node was used. Positivity for active caspase is shown using cytoplasmic staining . the number of apoptotic cells was measure per each high power filed (HPF) under light microscopy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interlukin-10 (IL-10) Serum Level</measure>
    <time_frame>Right before the intervention(3 days before surgery)</time_frame>
    <description>The concentration of IL-10 in the serum of patients was measured using a quantitative enzyme-linked immunosorbent assay (ELISA) kit .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin-10 (IL-10) Serum Level</measure>
    <time_frame>procedure (before anesthesia induction)</time_frame>
    <description>The concentration of IL-10 in the serum of patients was measured using a quantitative enzyme-linked immunosorbent assay (ELISA) kit .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin--10 (IL-10) Serum Level</measure>
    <time_frame>at the end of surgery after protamine reversal</time_frame>
    <description>The concentration of IL-10 in the serum of patients was measured using a quantitative enzyme-linked immunosorbent assay (ELISA) kit .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interleukin (IL-10) Serum Level</measure>
    <time_frame>the first postoperative day</time_frame>
    <description>The concentration of IL-10 in the serum of patients was measured using a quantitative enzyme-linked immunosorbent assay (ELISA) kit .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Growth Factor</measure>
    <time_frame>Right before the intervention(3 days before surgery)</time_frame>
    <description>The concentration of the IGF-1 was also measured by a quantitative ELISA kit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Growth Factor</measure>
    <time_frame>procedure (before anesthesia induction)</time_frame>
    <description>The concentration of the IGF-1 was also measured by a quantitative ELISA kit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Growth Factor</measure>
    <time_frame>at the end of surgery after protamine reversal</time_frame>
    <description>The concentration of the IGF-1 was also measured by a quantitative ELISA kit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Growth Factor</measure>
    <time_frame>the first postoperative day</time_frame>
    <description>The concentration of the IGF-1 was also measured by a quantitative ELISA kit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemorrhage After Surgery</measure>
    <time_frame>immediately after surgery</time_frame>
    <description>after the surgery all the hemorrhage of patients was collected by suctioning and the exact amount of bleeding has been reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Units Usage</measure>
    <time_frame>discharge 1 day</time_frame>
    <description>number of pack cell that was administered for the patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator Application</measure>
    <time_frame>discharge 1 day</time_frame>
    <description>period of time that the patient was on ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine Level</measure>
    <time_frame>immediately after surgery</time_frame>
    <description>The serum level of Creatinine in the patients which is a measurement of the kidney function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Cardiomyopathies</condition>
  <condition>Apoptosis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>35 patients that will receive placebo for 3 days and each day for 3 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
    <arm_group_label>vitamin D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Candidate for first-time elective CABG surgery for coronary artery disease (CAD)&#xD;
&#xD;
          2. Coronary artery surgery only (i.e. no valvular surgery)&#xD;
&#xD;
          3. Cardiopulmonary pump used during surgery&#xD;
&#xD;
          4. Vitamin D level below 30 ng/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Renal failure or creatinine level &gt;1.5 mg/dl&#xD;
&#xD;
          2. Previous use of vitamin D supplement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erfan Tasdighi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti university of medical science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>modarres Hospital</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <results_first_submitted>March 23, 2021</results_first_submitted>
  <results_first_submitted_qc>September 21, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2021</results_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Erfan Tasdighi</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Apoptosis</keyword>
  <keyword>Insulin-like growth factor-1</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Cardiopulmonary bypass</keyword>
  <keyword>Interleukin-10</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT04323852/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT04323852/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D</title>
          <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D</title>
          <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="6"/>
                    <measurement group_id="B2" value="58" spread="9"/>
                    <measurement group_id="B3" value="58.5" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Iran</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ejection Fraction</title>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="10"/>
                    <measurement group_id="B2" value="48" spread="9"/>
                    <measurement group_id="B3" value="47.5" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Myocardial infarction</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythrocyte sedimentation rate (ESR)</title>
          <units>mm/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13" spread="9"/>
                    <measurement group_id="B2" value="14" spread="8"/>
                    <measurement group_id="B3" value="13.6" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="3"/>
                    <measurement group_id="B2" value="27" spread="3"/>
                    <measurement group_id="B3" value="27" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>25 (OH)D</title>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.8" spread="6"/>
                    <measurement group_id="B2" value="12.1" spread="5"/>
                    <measurement group_id="B3" value="12.4" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hyperlipidemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Mellitus</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smokers</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family history of cardiovascular disease</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="35"/>
                    <count group_id="B2" value="35"/>
                    <count group_id="B3" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Caspase 2 Enzyme Level</title>
        <description>Caspase 2 enzyme activity in right atrial specimen measured by with immunohistochemistry staining The positive control and negative control were taken from human lymph node tissue. as for the control tissue a humane lymph node was used. Positivity for active caspase is shown using cytoplasmic staining . the number of apoptotic cells was measure per each high power filed (HPF) under light microscopy.</description>
        <time_frame>during the surgery, an average of 3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Caspase 2 Enzyme Level</title>
          <description>Caspase 2 enzyme activity in right atrial specimen measured by with immunohistochemistry staining The positive control and negative control were taken from human lymph node tissue. as for the control tissue a humane lymph node was used. Positivity for active caspase is shown using cytoplasmic staining . the number of apoptotic cells was measure per each high power filed (HPF) under light microscopy.</description>
          <units>cells/ HPF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.0"/>
                    <measurement group_id="O2" value="2.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Caspase 3 Enzyme Level, an Average of 3 Hours</title>
        <description>Caspase 3 enzyme activity in right atrial specimen measured by with immunohistochemistry staining The positive control and negative control were taken from human lymph node tissue. as for the control tissue a humane lymph node was used. Positivity for active caspase is shown using cytoplasmic staining . the number of apoptotic cells was measure per each high power filed (HPF) under light microscopy.</description>
        <time_frame>during the surgery, an average of 3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Caspase 3 Enzyme Level, an Average of 3 Hours</title>
          <description>Caspase 3 enzyme activity in right atrial specimen measured by with immunohistochemistry staining The positive control and negative control were taken from human lymph node tissue. as for the control tissue a humane lymph node was used. Positivity for active caspase is shown using cytoplasmic staining . the number of apoptotic cells was measure per each high power filed (HPF) under light microscopy.</description>
          <units>cells/ HPF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.8"/>
                    <measurement group_id="O2" value="2.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Caspase 7 Enzyme Level</title>
        <description>Caspase 7 enzyme activity in right atrial specimen measured by with immunohistochemistry staining The positive control and negative control were taken from human lymph node tissue. as for the control tissue a humane lymph node was used. Positivity for active caspase is shown using cytoplasmic staining . the number of apoptotic cells was measure per each high power filed (HPF) under light microscopy.</description>
        <time_frame>during the surgery, an average of 3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Caspase 7 Enzyme Level</title>
          <description>Caspase 7 enzyme activity in right atrial specimen measured by with immunohistochemistry staining The positive control and negative control were taken from human lymph node tissue. as for the control tissue a humane lymph node was used. Positivity for active caspase is shown using cytoplasmic staining . the number of apoptotic cells was measure per each high power filed (HPF) under light microscopy.</description>
          <units>cells/ HPF</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.0"/>
                    <measurement group_id="O2" value="1.8" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interlukin-10 (IL-10) Serum Level</title>
        <description>The concentration of IL-10 in the serum of patients was measured using a quantitative enzyme-linked immunosorbent assay (ELISA) kit .</description>
        <time_frame>Right before the intervention(3 days before surgery)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Interlukin-10 (IL-10) Serum Level</title>
          <description>The concentration of IL-10 in the serum of patients was measured using a quantitative enzyme-linked immunosorbent assay (ELISA) kit .</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.35"/>
                    <measurement group_id="O2" value="1.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin-10 (IL-10) Serum Level</title>
        <description>The concentration of IL-10 in the serum of patients was measured using a quantitative enzyme-linked immunosorbent assay (ELISA) kit .</description>
        <time_frame>procedure (before anesthesia induction)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin-10 (IL-10) Serum Level</title>
          <description>The concentration of IL-10 in the serum of patients was measured using a quantitative enzyme-linked immunosorbent assay (ELISA) kit .</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="4.9"/>
                    <measurement group_id="O2" value="1.0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin--10 (IL-10) Serum Level</title>
        <description>The concentration of IL-10 in the serum of patients was measured using a quantitative enzyme-linked immunosorbent assay (ELISA) kit .</description>
        <time_frame>at the end of surgery after protamine reversal</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin--10 (IL-10) Serum Level</title>
          <description>The concentration of IL-10 in the serum of patients was measured using a quantitative enzyme-linked immunosorbent assay (ELISA) kit .</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304.8" spread="85.6"/>
                    <measurement group_id="O2" value="205.5" spread="107.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interleukin (IL-10) Serum Level</title>
        <description>The concentration of IL-10 in the serum of patients was measured using a quantitative enzyme-linked immunosorbent assay (ELISA) kit .</description>
        <time_frame>the first postoperative day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin (IL-10) Serum Level</title>
          <description>The concentration of IL-10 in the serum of patients was measured using a quantitative enzyme-linked immunosorbent assay (ELISA) kit .</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="6.5"/>
                    <measurement group_id="O2" value="4.0" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Growth Factor</title>
        <description>The concentration of the IGF-1 was also measured by a quantitative ELISA kit</description>
        <time_frame>Right before the intervention(3 days before surgery)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Growth Factor</title>
          <description>The concentration of the IGF-1 was also measured by a quantitative ELISA kit</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3" spread="33.9"/>
                    <measurement group_id="O2" value="76.5" spread="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Growth Factor</title>
        <description>The concentration of the IGF-1 was also measured by a quantitative ELISA kit</description>
        <time_frame>procedure (before anesthesia induction)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Growth Factor</title>
          <description>The concentration of the IGF-1 was also measured by a quantitative ELISA kit</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.8" spread="63.2"/>
                    <measurement group_id="O2" value="75.0" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Growth Factor</title>
        <description>The concentration of the IGF-1 was also measured by a quantitative ELISA kit</description>
        <time_frame>at the end of surgery after protamine reversal</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Growth Factor</title>
          <description>The concentration of the IGF-1 was also measured by a quantitative ELISA kit</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.0" spread="67.1"/>
                    <measurement group_id="O2" value="82.1" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Growth Factor</title>
        <description>The concentration of the IGF-1 was also measured by a quantitative ELISA kit</description>
        <time_frame>the first postoperative day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Growth Factor</title>
          <description>The concentration of the IGF-1 was also measured by a quantitative ELISA kit</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.6" spread="61.2"/>
                    <measurement group_id="O2" value="69.4" spread="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemorrhage After Surgery</title>
        <description>after the surgery all the hemorrhage of patients was collected by suctioning and the exact amount of bleeding has been reported.</description>
        <time_frame>immediately after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Hemorrhage After Surgery</title>
          <description>after the surgery all the hemorrhage of patients was collected by suctioning and the exact amount of bleeding has been reported.</description>
          <units>cc</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360.7" spread="237.7"/>
                    <measurement group_id="O2" value="404.4" spread="245.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Units Usage</title>
        <description>number of pack cell that was administered for the patient</description>
        <time_frame>discharge 1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Units Usage</title>
          <description>number of pack cell that was administered for the patient</description>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.7"/>
                    <measurement group_id="O2" value="0.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator Application</title>
        <description>period of time that the patient was on ventilator</description>
        <time_frame>discharge 1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator Application</title>
          <description>period of time that the patient was on ventilator</description>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="2.3"/>
                    <measurement group_id="O2" value="8.3" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine Level</title>
        <description>The serum level of Creatinine in the patients which is a measurement of the kidney function</description>
        <time_frame>immediately after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine Level</title>
          <description>The serum level of Creatinine in the patients which is a measurement of the kidney function</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".8" spread=".05"/>
                    <measurement group_id="O2" value=".9" spread=".04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D</title>
          <description>35 patients that pass the inclusion criteria and do not have exclusion criteria that will receive Vitamin D for 3 days and each time 3 doses of 50000 units&#xD;
Vitamin D: Participants undergoing coronary artery bypass graft (CABG) surgery are randomly allocated to group A (intervention), who receive 3 doses of vitamin D (50000 U) a day for 3 days before surgery</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>35 patients that will receive placebo for 3 days and each day for 3 doses&#xD;
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>heart attack</sub_title>
                <description>A heart attack happens when the flow of oxygen-rich blood in one or more of the coronary arteries, which supply the heart muscle, suddenly becomes blocked, and a section of heart muscle can't get enough oxygen</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal bleeding</sub_title>
                <description>Gastrointestinal (GI) bleeding is a symptom of a disorder in your digestive tract. The blood often appears in stool or vomit but isn't always visible, though it may cause the stool to look black or tarry</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>brain stroke</sub_title>
                <description>A stroke occurs when the blood supply to part of your brain is interrupted or reduced, preventing brain tissue from getting oxygen and nutrients</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <description>The invasion and growth of germs in the body</description>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DVT</sub_title>
                <description>Deep vein thrombosis (DVT) is a medical condition that occurs when a blood clot forms in a deep vein</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Although this single-center study had a relatively small sample size and was limited to cardiac surgery patients, the study design was RCT with homogenous patients.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. ََAfshin Zarghi</name_or_title>
      <organization>Shahid Beheshti Medical School</organization>
      <phone>021-22439781</phone>
      <email>Mpajouhesh@sbmu.ac.ir</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

